Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome.
Phase of Trial: Phase III
Latest Information Update: 28 Sep 2016
At a glance
- Drugs Clobazam (Primary)
- Indications Lennox-Gastaut syndrome
- Focus Therapeutic Use
- Sponsors Lundbeck Inc
- 28 Sep 2016 Results of post-hoc analysis from OV-1004 and OV-1012 studies (n=200) published in the Neurology.
- 28 Sep 2016 According to Lundbeck A/S media release, Barry Gidal, PharmD, University of Wisconsin School of Pharmacy & Dept. of Neurology is the lead investigator of the post-hoc analyses
- 21 Apr 2016 Results of a post hoc analysis presented at the 68th Annual Meeting of the American Academy of Neurology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History